These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31332222)

  • 1. Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants.
    Salati S; Genovese E; Carretta C; Zini R; Bartalucci N; Prudente Z; Pennucci V; Ruberti S; Rossi C; Rontauroli S; Enzo E; Calabresi L; Balliu M; Mannarelli C; Bianchi E; Guglielmelli P; Tagliafico E; Vannucchi AM; Manfredini R
    Sci Rep; 2019 Jul; 9(1):10558. PubMed ID: 31332222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN.
    Benlabiod C; Cacemiro MDC; Nédélec A; Edmond V; Muller D; Rameau P; Touchard L; Gonin P; Constantinescu SN; Raslova H; Villeval JL; Vainchenker W; Plo I; Marty C
    Nat Commun; 2020 Sep; 11(1):4886. PubMed ID: 32985500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish.
    Lim KH; Chang YC; Chiang YH; Lin HC; Chang CY; Lin CS; Huang L; Wang WT; Gon-Shen Chen C; Chou WC; Kuo YY
    Blood Cancer J; 2016 Oct; 6(10):e481. PubMed ID: 27716741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice.
    Toppaldoddi KR; da Costa Cacemiro M; Bluteau O; Panneau-Schmaltz B; Pioch A; Muller D; Villeval JL; Raslova H; Constantinescu SN; Plo I; Vainchenker W; Marty C
    Oncogene; 2019 Mar; 38(10):1651-1660. PubMed ID: 30846848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.
    Marty C; Pecquet C; Nivarthi H; El-Khoury M; Chachoua I; Tulliez M; Villeval JL; Raslova H; Kralovics R; Constantinescu SN; Plo I; Vainchenker W
    Blood; 2016 Mar; 127(10):1317-24. PubMed ID: 26608331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.
    Han L; Schubert C; Köhler J; Schemionek M; Isfort S; Brümmendorf TH; Koschmieder S; Chatain N
    J Hematol Oncol; 2016 May; 9(1):45. PubMed ID: 27177927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Mutated Calreticulin in the Pathogenesis of
    Vadeikienė R; Jakštys B; Laukaitienė D; Šatkauskas S; Juozaitytė E; Ugenskienė R
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.
    Pietra D; Rumi E; Ferretti VV; Di Buduo CA; Milanesi C; Cavalloni C; Sant'Antonio E; Abbonante V; Moccia F; Casetti IC; Bellini M; Renna MC; Roncoroni E; Fugazza E; Astori C; Boveri E; Rosti V; Barosi G; Balduini A; Cazzola M
    Leukemia; 2016 Feb; 30(2):431-8. PubMed ID: 26449662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.
    Loghavi S; Bueso-Ramos CE; Kanagal-Shamanna R; Ok CY; Salim AA; Routbort MJ; Mehrotra M; Verstovsek S; Medeiros LJ; Luthra R; Patel KP
    Am J Clin Pathol; 2016 Mar; 145(3):418-27. PubMed ID: 27124925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms.
    Mózes R; Gángó A; Sulák A; Vida L; Reiniger L; Timár B; Krenács T; Alizadeh H; Masszi T; Gaál-Weisinger J; Demeter J; Csomor J; Matolcsy A; Kajtár B; Bödör C
    Pathology; 2019 Apr; 51(3):301-307. PubMed ID: 30606612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of calreticulin mutations in myeloproliferative neoplasms.
    Araki M; Komatsu N
    Int J Hematol; 2020 Feb; 111(2):200-205. PubMed ID: 31848992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin.
    Edahiro Y; Araki M; Komatsu N
    Cancer Sci; 2020 Aug; 111(8):2682-2688. PubMed ID: 32462673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
    Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
    Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms.
    Araki M; Komatsu N
    Cancer Sci; 2017 Oct; 108(10):1907-1912. PubMed ID: 28741795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calreticulin mutations in myeloproliferative neoplasms.
    Shide K
    Int Rev Cell Mol Biol; 2021; 365():179-226. PubMed ID: 34756244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of myeloproliferative neoplasms by mutant calreticulin: underlying mechanisms].
    Araki M
    Rinsho Ketsueki; 2018; 59(8):1072-1077. PubMed ID: 30185708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms.
    Gángó A; Mózes R; Boha Z; Kajtár B; Timár B; Király PA; Kiss R; Fésüs V; Nagy N; Demeter J; Körösmezey G; Borbényi Z; Marton I; Szőke A; Masszi T; Farkas P; Várkonyi J; Plander M; Pósfai É; Egyed M; Pál K; Radványi G; Hamed A; Csomor J; Matolcsy A; Alpár D; Bödör C
    Leuk Res; 2018 Feb; 65():42-48. PubMed ID: 29306106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Calreticulin gene and myeloproliferative neoplasms.
    Clinton A; McMullin MF
    J Clin Pathol; 2016 Oct; 69(10):841-5. PubMed ID: 27354406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.